Certara Inc (CERT)vsNovartis AG ADR (NVS)
CERT
Certara Inc
$6.13
+3.90%
HEALTHCARE · Cap: $904.62M
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 13408% more annual revenue ($56.58B vs $418.84M). NVS leads profitability with a 23.9% profit margin vs -0.4%. NVS earns a higher WallStSmart Score of 51/100 (C-).
CERT
Avoid34
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+65.2%
Fair Value
$19.89
Current Price
$6.13
$13.76 discount
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
3.3% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Operating margin of 2.1%
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : CERT
The strongest argument for CERT centers on Price/Book.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : CERT
The primary concerns for CERT are Revenue Growth, Altman Z-Score, Market Cap.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
CERT profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.
CERT carries more volatility with a beta of 1.62 — expect wider price swings.
CERT is growing revenue faster at 3.3% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 34/100), backed by strong 23.9% margins. CERT offers better value entry with a 65.2% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Certara Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Certara Inc. provides software products and technology services to clients for biosimulation in drug discovery, preclinical and clinical research, regulatory filings, and market access. The company is headquartered in Princeton, New Jersey.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other HEALTH INFORMATION SERVICES Stocks
Want to dig deeper into these stocks?